Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to access the efficacy and safety of MC2-25 cream and MC2-25 vehicle for treatment of chronic kidney disease associated pruritus (CKD)-aP).


Clinical Trial Description

In this trial, subjects who fulfil all inclusion and exclusion criteria are enrolled. Eligible subjects will be randomised in a 2:1 ratio to MC2-25 cream or MC2-25 vehicle, respectively. The subjects will apply the assigned investigational medicinal product (IMP) twice daily for 12 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05482698
Study type Interventional
Source MC2 Therapeutics
Contact
Status Completed
Phase Phase 2
Start date July 1, 2022
Completion date February 2, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03532568 - Klotho in Chronic Kidney Disease-associated Pruritis (CKD-aP) N/A
Withdrawn NCT05625542 - Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis Patients
Not yet recruiting NCT06466421 - Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis Phase 4
Active, not recruiting NCT05524467 - Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients